Metropolis Healthcare has unveiled its FY27 growth strategy, focusing on volume-led expansion and a transition to specialty diagnostics. With Q1 FY27 revenue up 17% YoY to ₹450 crore and EBITDA margins expanding by 210 bps, the management plans to grow revenue by 14-15% this fiscal year. The strategy relies on expanding its network to 1,000 centers, scaling the TruHealth segment, and enhancing asset utilization. Investors are watching the company’s ability to integrate specialty diagnostics and maintain operational efficiency in a competitive market.
Metropolis Healthcare Outlines FY27 Growth Strategy Following Strong Q1
Revenue grew 17% YoY to ₹450 crore in Q1 FY27; EBITDA margins expanded by 210 bps to 25.2%.
Reader Takeaway: Strong volume-led demand and operational leverage are driving growth, though successful integration of acquisitions remains critical.
What just happened
Metropolis Healthcare presented its FY27 outlook at an Investor & Analyst Meet. The company confirmed a clear roadmap targeting 14-15% revenue growth for the full year and 100-150 bps improvement in EBITDA margins. This guidance is built on a volume-led approach rather than price increases, reflecting a focus on sustainable demand.
Strategic Growth Engines
The company is betting on five pillars to compound capital: expanding to 1,000 owned centers over three years, scaling the TruHealth wellness platform, increasing specialty and genomics testing revenue, leveraging digital AI tools, and continuing a selective M&A strategy to deepen geographic reach. The genomics portfolio has already doubled in scale following recent acquisitions.
Why this matters
Metropolis is actively shifting toward higher-margin specialty diagnostics. By improving its lab-to-center ratio—moving from 24:1 to 35:1—the company aims to extract more value from existing assets. Tier 3 market penetration is also yielding results, with those regions reporting a 25% revenue jump in the latest quarter.
Risks to watch
Success depends on the company's ability to maintain high utilization rates while integrating acquired entities into its national diagnostic network. The execution of these long-term goals assumes a stable regulatory and competitive environment, both of which remain fluid in the organized diagnostic space.
Context metrics (FY26)
In the previous fiscal year, Metropolis reported ₹1,646 crore in revenue, ₹401 crore in EBITDA, and a profit after tax of ₹191 crore, providing a solid foundation for its current growth targets.